Peptide news, regulation & research, verified daily.

PeptideKnow tracks FDA and HHS actions, clinical trial readouts and the science behind 128 research peptides, with every claim linked to its primary source.

Peptide profiles
128
News reports
68
Dosage protocols
121
Categories
21

Regulatory tracker

Where the most-searched peptides stand

FDA approval, compounding and trial status, updated as rules change. Not medical or legal advice.

What changed in October
PeptideStatusLatest coverage
BPC-157Healing & Recovery Compounding under HHS policy HHS Peptide Compounding Policy: BPC-157, TB-500 & More
TB-500Healing & Recovery Compounding under HHS policy HHS Peptide Compounding Policy: BPC-157, TB-500 & More
RetatrutideWeight Loss & Metabolic Clinical trials Medicare GLP-1 Bridge: $50 Obesity Drug Coverage Begins
SemaglutideWeight Loss & Metabolic FDA-approved Medicare GLP-1 Bridge: $50 Obesity Drug Coverage Begins
TirzepatideWeight Loss & Metabolic FDA-approved Generic Tirzepatide: FDA Accepts Sandoz ANDAs
GHK-CuSkin & Hair PCAC review pending Inside the Peptide Gray Market and FDA Advisory Panel
MOTS-cMitochondrial Compounding under HHS policy FDA PCAC Briefing Docs on Compounded Peptides (July 2026)
KPVHealing & Recovery Compounding under HHS policy FDA PCAC Briefing Docs on Compounded Peptides (July 2026)
EpithalonAnti-Aging & Longevity Compounding under HHS policy Peptide Import Inspections and Compounding (2026)
SemaxCognitive & Nootropic Compounding under HHS policy Inside the Peptide Gray Market and FDA Advisory Panel
LL-37Antimicrobial PCAC review pending FDA PCAC Peptide Meeting: BPC-157, TB-500, Semax
DSIPSleep Not approved · PCAC voted no BPC-157 Compounding: What the FDA PCAC Review Means
IpamorelinGrowth Hormone Secretagogues FDA Category 2 Alabama Bans Research-Grade Peptide Prescribing
PT-141Sexual Health FDA-approved State Pharmacy Board Peptide Enforcement in 2026
FDA-approved In clinical trials Compounding under HHS policy PCAC review pending FDA Category 2 Not approved

Most read profiles

Peptides A–Z
Healing & RecoveryCompounding under HHS policy

BPC-157

BPC-157 is a synthetic 15-amino acid peptide derived from a naturally occurring protective protein isolated from human gastric juice.

Research dose200-500 mcg/day
Weight Loss & MetabolicClinical trials

Retatrutide

Retatrutide is an investigational first-in-class triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously.

Research dose1-12 mg/week (Phase II range)
Healing & RecoveryCompounding under HHS policy

TB-500

TB-500 is a synthetic heptapeptide corresponding to the N-acetylated active fragment (amino acids 17–23) of the endogenous 43-amino acid signaling …

Research dose2-5 mg/week
Weight Loss & MetabolicFDA-approved

Semaglutide

Semaglutide is an FDA-approved synthetic 31-amino acid analog of glucagon-like peptide-1 (GLP-1), modified with a C18 fatty acid chain via a linker…

Research dose0.25-2.4 mg/week (subcutaneous); 3-14 mg/day (oral)
Skin & HairPCAC review pending

GHK-Cu

GHK-Cu is a naturally occurring tripeptide copper complex (glycyl-L-histidyl-L-lysine) first identified in human plasma in the 1970s.

Research dose1-2 mg/day injectable; topical concentrations 0.1-2%
Weight Loss & MetabolicFDA-approved

Tirzepatide

Tirzepatide is an FDA-approved first-in-class dual GIP/GLP-1 receptor agonist peptide that simultaneously activates both glucose-dependent insulino…

Research dose2.5-15 mg/week
MitochondrialCompounding under HHS policy

MOTS-c

MOTS-c is a 16-amino acid mitochondrial-derived peptide (MDP) encoded by a short open reading frame within the 12S rRNA gene of mitochondrial DNA.

Research dose5-10 mg/week
Growth Hormone SecretagoguesFDA Category 2

Ipamorelin

Ipamorelin is a selective synthetic pentapeptide growth hormone secretagogue, developed as part of a major chemistry program targeting GHRP analogs.

Research dose200-300 mcg/dose, 1-3x/day

Questions

Frequently asked questions

What is PeptideKnow?

An independent reference and news site covering 128 research peptides, with mechanisms of action, dosage protocols from published research, stacking guides, clinical data and daily regulatory news, including FDA compounding rules under sections 503A and 503B.

Are research peptides FDA-approved?

Most are not. BPC-157, TB-500 and MOTS-c are not FDA-approved drugs. A few peptides, such as semaglutide, tirzepatide, tesamorelin and bremelanotide (PT-141), are approved for specific indications. Each profile shows its current status.

Where does PeptideKnow get its data?

From primary sources: FDA and HHS announcements and dockets, the Federal Register, ClinicalTrials.gov, PubMed-indexed research and company disclosures. Every news report links to the documents it relies on.

How often is PeptideKnow updated?

The news section is updated every day. Peptide profiles are revised whenever regulatory status or trial data changes.